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Purpose: To study a novel and fast optical coherence tomography (OCT) device for
home-based monitoring in age-related macular degeneration (AMD) in a small sample
yielding sparse OCT (spOCT) data and to compare the device to a commercially
available reference device.
Methods: In this prospective study, both eyes of 31 participants with AMD were
included. The subjects underwent scanning with an OCT prototype and a spectral-
domain OCT to compare the accuracy of the central retinal thickness (CRT)
measurements.
Results: Sixty-two eyes in 31 participants (21 females and 10 males) were included.
The mean age was 79.6 years (age range, 69–92 years). The mean difference in the CRT
measurements between the devices was 4.52 lm (SD 6 20.0 lm; range, 65.6 to 41.5
lm). The inter- and intrarater reliability coefficients of the OCT prototype were both
.0.95. The laser power delivered was ,0.54 mW for spOCT and ,1.4 mW for SDOCT.
No adverse events were reported, and the visual acuity before and after the
measurements was stable.
Conclusion: This study demonstrated the safety and feasibility of this home-based
OCT monitoring under real-life conditions, and it provided evidence for the potential
clinical benefit of the device.
Translational Relevance: The newly developed spOCT is a valid and readily available
retina scanner. It could be applied as a portable self-measuring OCT system. Its use
may facilitate the sustainable monitoring of chronic retinal diseases by providing
easily accessible and continuous retinal monitoring.
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Introduction
Optical coherence tomography (OCT) is a nonin-
vasive imaging technique used to capture cross-
sectional images of the retina.1,2 The OCT retina-
mapping software analyzes both qualitative and
quantitative changes, based on eye conditions that
may be diagnosed or monitored longitudinally,
including age-related macular degeneration
(AMD),3–5 retinal vein occlusion,6–9 and diabetic
retinopathy.10–12
These three pathologies often cause gradual vision
loss and blindness.13,14 Therefore, it is important to
detect pathologic changes in the retina early to allow
for timely treatment, which results in better out-
comes9 and reduction in the significant long-term
costs of health care systems.15–17 Because frequent
medical visits impose a great burden of treatment on
patients and clinics, a novel, more compact prototype
of a self-measuring OCT device was developed and
designed for OCT scanning in elderly patients. The
downscaled proportions of the device allowed for its
portability and reduced size. Thus, the sparse OCT
(spOCT) pattern enabled very fast scanning, and it is
potentially suitable for use at home or outside the
clinical setting.18
We propose a novel home-based retina monitoring
that could be very useful for seamless monitoring and
OCT data communication in a wide range of retinal
diseases beyond AMD—such as myopic choroidal
neovascularization, diabetic macular edema, retinal
vein occlusion, and chronic central serous chorior-
etinopathy—in short, in every eye disease that is
associated with the accumulation of pathologic fluid
in the retina or beneath.
In this article we report, we believe for the first
time, the performance of this portable spOCT system
and compare it with a standard desktop OCT with
regard to feasibility, scan quality, and the patient’s
comfort and safety.
Methods
This study was designed as a prospective, open-
label, nonrandomized investigation to assess the
prototype of a novel OCT retina scanner intended
for the self-measuring and monitoring of retinal
pathologies. Approval for the study was obtained
from the local ethics committee (KEK-ZH-Nr: 2015-
0316) and Swissmedic (ID no. 2015-MD-0015).
Written informed consent was obtained in advance
from each participant in this study, which adhered to
the tenets of the Declaration of Helsinki.
Investigational Device
The investigational medical device (IMD) consist-
ed of a spectral-domain OCT prototype (marked as
MIMO_02), which was developed at the ARTORG
Center (Bern, Switzerland) and the Institute for
Human Centered Engineering OptoLab at the Uni-
versity of Applied Sciences Engineering and Informa-
tion Technology (Biel/Berne, Switzerland). A
superluminescent diode-generated light (SLED) with
a 52.5-nm full-width half-maximum spectral band-
width at a center wavelength of 841 nm was guided
into a fiber coupler and divided into sample and
reference arms by a 50/50 beam splitter. It was
possible to operate the system in different densities on
data samples (Fig. 1). To illustrate the high imaging
capabilities of the new OCT device, a single line scan
pattern with parameters comparable to the reference
device was performed on the same healthy eye (Fig.
2). In both OCT systems, the scan length was 5 mm.
The IMD had a high sample resolution of 400 pixels
with an A-scan rate of 15 kHz. The averaging of
maximal 22 B-scans was possible at this time. The
OCT (Spectralis; Heidelberg Engineering, Heidelberg,
Germany) single line acquisition had a resolution of
768 pixels, with an average automatic real-time
tracking of 25 B-scans, excluding the technique of
enhanced depth imaging.
In addition, the IMD was able to operate the small
sample acquisition method, spOCT. This novel
volume scan protocol was established to investigate
extremely fast volume scanning capabilities, generat-
ing an optical specimen of a cube 3.83 3.8 mm with
resolutions of 503 50 pixels, 1003 100 pixels, or 150
3 150 pixels; a scan depth of 4.2 mm; and a depth
resolution of 2048 pixels. Because the A-scan rate of
the prototype spOCT was tunable, it was adjusted to
15 kHz.
The ergonomics of the spOCT device with minimal
operator interaction was enhanced and improved by
inclining the subject’s head in a novel position (Fig.
2A, 2B). The head was laid on a specific headrest. It
was stabilized by the weight of the head itself to
provide maximum comfort and reduce moving
artifacts. Because the investigational scanner was a
prototype, it did not feature all the lay-user operating
interfaces. Therefore, during this study a qualified
engineer operated the device in some of the examina-
tion procedures.
2 TVST j 2018 j Vol. 7 j No. 4 j Article 8
Maloca et al.
Downloaded From: https://tvst.arvojournals.org/pdfaccess.ashx?url=/data/journals/tvst/937352/ on 08/28/2018
Intended Use
The performance of the newly developed spOCT
device was compared with a standard OCT (SDOCT,
Spectralis; Heidelberg Engineering, Heidelberg, Ger-
many). The overall objective of this study was to
obtain and assess the functionality and specific
aspects of the spOCT prototype, such as diagnostic
performance and patient experience during acquisi-
tion, which are necessary for its improvement. The
primary objective of the study was to perform a
comparative analysis of the measurements of the
central retinal thickness (CRT) captured by the
investigational and reference device. The secondary
objective of the study was to collect data on the
measurement duration and to collect and evaluate
patient comfort during the examination with the
spOCT.
Study Population
Patients with AMD visiting the Department of
Ophthalmology at the University Hospital Zurich in
Zurich, Switzerland, were prospectively recruited for
the study. The inclusion criteria were as follows:
German-speaking adults with and an established
diagnosis of AMD. To reflect accurately real-world
conditions, all stages of AMD, including geographic
atrophy and fibrovascular scarring, were included. To
challenge the new device, ocular comorbidities, such
as any degree of cataract, dry eye syndrome, and
glaucoma, were accepted for inclusion, which facili-
tated the identification of potential problems that
future patients would have in using the device.
The exclusion criteria were as follows: other
comorbidities, such as epilepsy, dementia, Parkin-
son’s disease, serious mental health illness, develop-
mental disability or cognitive impairment; any general
disability that would preclude the patient’s adequate
comprehension of the informed consent; subjects who
did not sign informed consent; and subjects who used
electronic medical devices (e.g., hearing aid, cochlear
implant, pacemaker, defibrillator, or infusion pump)
in order to ensure the highest possible electromagnetic
safety.
Sample Size Calculation
Considering the overall objective of the study (i.e.,
to collect data on the functionality of the spOCT to
improve imaging performance and patient comfort),
30 participants were deemed sufficient to identify the
major design deficiencies that would inform the
subsequent developmental steps. Therefore, in this
pilot study, the number of patients was based on the
usability literature.19
Clinical Data Collection
All patients selected for the study were assigned to
the same investigation procedure. To test the objec-
tives of the clinical investigation, the performances of
the spOCT and the commercial SDOCT scanner were
compared. For this reason, the eyes of the study
participants were scanned with both OCT systems,
and the CRT values were then compared using a
pairwise sample analysis. Additionally, the duration
of the retinal measurement carried out by both
devices was recorded. After the scanning procedure,
the subjects were interviewed about their perceptions
and comfort during the OCT.
Because the spOCT was not yet equipped with the
fully automatic analysis software, the retinal thickness
on the spOCT scans was measured manually by one
grader using custom software written in MATLAB
(MATLAB R 2017a; The MathWorks, Inc., Natick,
MA).
The quantitative OCT analysis of the reference
device was performed manually by a second, inde-
pendent grader using the manufacturer’s built-in
caliber software tool (Spectralis HRA Version
1.9.13.0, Viewing Module 6.5.2.0; Heidelberg Engi-
neering).
To determine the safety performance of the
prototype, visual acuity (VA) was measured before
and after scanning with the spOCT using charts from
the Early Treatment Diabetic Retinopathy Study
Figure 1. Comparison of standard Heidelberg Spectralis desktop
OCT to novel investigational spOCT. (A) Scanning laser
ophthalmoscopy (SLO) of AMD. (B) Corresponding cross-section
scan of the same eye as in (A) with illustration of manual central
retinal thickness (CRT) measurement of standard Spectralis OCT (B)
and spOCT (C). Note that in the spOCT system the scan resolution,
thus the redundancy of image information, is reduced to allow
rapid and repeated measurement of OCT volumes. However,
despite the low sampling, CRT measurement was achieved in
spOCT images comparable to the reference device.
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Figure 2. Illustration and performance of the novel sparseOCT device (spOCT, MIMO_02) compared to standard Heidelberg Spectralis
desktop OCT. (A) Illustration of the complete prototype spOCT (black box) shows compact design and novel headrest position to reduce
moving artifacts. (B) The direction of the light beam can be adjusted to the position of the subject to provide a comfortable user
experience. High sample recording of the single line scan of a healthy macula obtained by spOCT (C) compared to Heidelberg desktop
OCT (D) of the same eye with comparable scan settings.
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(ETDRS). Any adverse events (AEs), serious adverse
events (SAEs), and/or serious adverse device effects
(SADEs) were collected, fully investigated, and report-
ed if and when they occurred in the course of the study.
Clinical Investigation: Primary Objective
To achieve the primary objective, a true/false
criterion was applied to determine whether the
measurement of the distance between the inner
limiting membrane (ILM) of the retina and retinal
pigment epithelium (RPE) (i.e., CRT, ILM to RPE
distance) was successful. After the CRT measurement
was performed, the CRT thickness was measured (in
micrometers) by using both the investigative and the
reference devices.
The CRT was measured to obtain a relatively easy
and comparable landmark in both devices. Indeed,
the new OCT device is intended to operate with a
specifically designed artificial intelligence software
that is capable of automatically analyzing the intra-
and subretinal changes in a diseased retina.
The reproducibility of the investigative medical
device was assessed by determining the inter- and
intrarater reliability coefficients. The differences in
CRT measurements between the spOCT and the
reference device in the range of CRT values were
graphically analyzed by a Bland-Altman plot. Finally,
to evaluate further the measurement quality and to
contextualize the performance of the prototype
spOCT, the results of a study that compared CRT
measurements in healthy eyes according to six
different commercially available OCT instruments
were used as a benchmark.20
Clinical Investigation: Secondary Objective
To achieve the secondary objective, the patients’
narrative descriptions of their comfort during the
examination with the spOCT were evaluated. The
goal was to collect and assess the participants’
feedback on how the device should be modified in
order to improve patient comfort during the OCT
imaging. The descriptions were not quantified.
In addition, the duration of the acquisition with
the spOCT was recorded. Documentation of the
acquisition time started with the calibration of the
device and ended after the first OCT measurement
was performed.
Clinical Investigation: Safety Objective
The safety objective was formulated as the change
in the logarithmic minimum angle of resolution
(logMAR) measured using an ETDRS test chart
before and after the nonmydriatic measurements were
taken. One letter on the chart represents 0.02
logMAR units. The VA was measured before and
after the examination using the spOCT. Potentially,
the side effects (e.g., nervousness or dry eyes) of an
OCT examination could temporarily reduce the VA if
patients do not blink enough. If the VA score differed
by more than 0.1 logMAR (i.e., a change of more
than five letters) before and after the OCT imaging, a
repeated measurement was performed 15 minutes
later to exclude the temporary side effects. In cases
where the remeasured VA difference was still greater
than 0.1 logMAR, the primary investigator (PI)
examined the eye for AE and, if necessary, took
appropriate measures.
Data Quality Assurance
For each participant enrolled in the study, an
anonymized case report form (CRF) was completed
and signed by the PI. The participants’ identities were
coded using a participant identification number
(INU). The data analysis and outcome evaluation
were performed using anonymized data; no other
blinding procedures were applied.
The procedure used to conduct the study was fully
documented, and the study data were subsequently
verified as required by ISO 14155 and local regula-
tions. Any CRF entries and corrections were per-
formed by staff members on site and authorized by
the PI. The entries were checked using the Integrated
Scientific Services’ study monitor (ISS AG, Biel,
Switzerland), and any errors or inconsistencies were
then clarified. At the end of the study, the ISS AG
collected original, completed, and signed CRFs. Their
copies were stored at the study site.
The data were collected using the custom-built
software program (OpenClinica Database Version
3.13; ISS AG). Double data entry was applied. The
data processing was performed using OpenClinica
and its query management. The narrative data and
commentaries were controlled visually. All requests
for information and clarification were responded to at
the investigational site. The data were then exported
as indexed lists into a statistics program (JMP 9; SAS
Institute Inc., Cary, NC) for the final analysis.
Statistical Analysis
The descriptive statistics were computed for the
CRT measurements and for the duration of the OCT
examination performed using the spOCT. Before and
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after this examination, the change in the VA score was
calculated for each examined participant. The pa-
tients’ narrative descriptions of their comfort during
the OCT scanning were not analyzed statistically.
The reproducibility of the method used to inves-
tigate the medical device was assessed by determining
the inter- and intrarater reliability coefficients ac-
cording to Eliasziw et al.21 Three randomly selected
raters performed three CRT measurements of 12 eyes
in six randomly selected patients.
A Bland-Altman plot22 was used to show the
differences in CRT measurements between the spOCT
and the reference device in the range of the obtained
CRT values. A paired Student’s t-test was performed
to determine whether the spOCT values were signif-
icantly different from the reference measurements.
The data were analyzed using the statistics
software R (https://www.r-project.org/; provided free
in the public domain by R Core Team 2017, R
Foundation for Statistical Computing, Vienna, Aus-
tria). R provides a language and environment for
statistical computing using the package irr for the
reliability coefficients and the package BlandAltman-
Leh for the Bland-Altman plot.
Results
Patient Demographics
A total of 62 eyes in 31 participants (68% females
[N ¼ 21] and 32% males [N ¼ 10]) who met the
inclusion criteria were recruited for OCT retinal
examination by the investigational and reference
devices. The overall median average age was 79 years
(age range, 68–92 years). The median age of the
female patients was 78 years (age range, 70–92 years),
and the median age of the male patients was 79.5
years (age range, 68–85 years).
The characteristics of dry eye syndrome were
observed in nine patients. Thirty-one eyes had clinical
signs of cataract development, and 31 were pseudo-
phakic. One patient was diagnosed with ocular
hypertension, one with corneal scarring, and one with
posterior capsule opacification. One patient presented
with a tremor caused by a previous cortisone
inhalation.
From 62 eyes, three eyes (patients 16, 19, 29) were
not examined by the spOCT because of technical
issues related to the power supply or media opacity
secondary to corneal scarring. Two eyes (patients 19,
29) could not be measured by the reference device for
the reasons described above. Furthermore, one eye
was excluded from the analysis because the off-target
measurement produced by the spOCT prototype was
too high. To allow the pairwise analysis, two eyes that
were examined by the reference scanner were also
excluded from the macular thickness analysis.
Quantitative Analysis of Central Retinal
Thickness as the Primary Objective
The Bland-Altman plot in Figure 3 shows the
differences between the prototype and the commercial
scanner according to the range of 58 CRT values
measured and included in the analysis. The differences
ranged between 65.6 and þ41.5 lm with a mean of
Figure 3. Bland-Altman plot of difference against the mean of spOCT scanner and Heidelberg Spectralis (reference) measurements of
CRT (lm). The lines represent mean difference (solid) and mean61.96 standard deviations (dashed) as the 95% limits of agreement. Sixty-
nine percent of the differences are in the range of 620 lm (dotted lines).
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4.52 lm (SD ¼ 20.00 lm), which was equivalent to
2.5% of the mean of reference measurements with
181.26 lm. Seventeen spOCT measurements deviated
by .20 lm from the reference value.
In 38 (65%) of the 58 eyes, the difference in CRT
measured with the spOCT was within 610% of the
respective reference value. In 13 eyes, the values
differed by more than 610% and less than 620%. In
six eyes the values were greater than 620% but less
than 630%. The difference in the CRT measurements
obtained using the two devices was not statistically
significant (paired t-test, two-sided, t ¼ 1.7198, df ¼
57, P¼ 0.091).
The CRT values of 12 eyes in six randomly selected
patients were measured by three randomly selected
raters. The results showed an intrarater reliability
coefficient of 0.968 (lower bound of one-sided 95%
confidence interval [CI]: 0.935) and an interrater
reliability coefficient of 0.958 (lower bound of one-
sided 95% CI: 0.917). The individual intrarater
reliabilities for each rater with their lower bound of
a one-sided 95% CI were 0.973 (0.940), 0.947 (0.885),
and 0.987 (0.971).
Qualitative OCT Image Comparison
The cross-section OCT image information derived
from the spOCT using high sample acquisition
parameters was shown to be comparable with the
SDOCT reference device (Fig. 2C, 2D). In the spOCT
image, the retinal zones appeared less blurred and the
retinal vessels were slightly better demarcated. The
choroid and the vitreous were more easily recogniz-
able in the Spectralis scan, but they were associated
with more speckle noise. Because the device was
designed to fulfill its intended purpose, a quick and
easily repeatable measurement, the small sample OCT
acquisition (spOCT), showed a more pixelated and
grainy image (Fig. 1C).
Secondary Objective
The patients’ narrative feedback on their comfort
during the OCT imaging procedure is summarized in
Table 1. Commentaries were obtained from 19 AMD
patients. Only five patients reported mild discomfort
related to the nosepiece material of the spOCT.
The length of the retinal assessment procedure
included the phase between device calibration and the
first OCT measurement, which was on average 2.51
Table. Summary of Patient Feedback on the Examination Performed With the Investigational, spOCT Device
and Reference OCT System
Patient Comment
Number of
Occurrences Patient INU
Examination with the spOCT
spOCT was convenient, overall positive feedback 5 11, 13,a 14, 26, 27
No complaints 2 2, 6
Headrest was comfortable 2 12, 14
Nosepiece felt too hard 2 1, 23
No complaints about the nosepiece 1 27
No complaints about the forehead pad 1 10
Cavity slope too large 1 1
Pressure on the cheeks and knuckle, felt harder than the reference device 1 3
Cavity sideways less deflected than in the reference medical device 1 4
Difficult to spot a crosshair pointer 1 5
Sitting position precluded an optimal breathing 1 7
Uneasy sitting position during the examination (patient had neck problems) 1 15
Nosepiece caused pain 1 13
Nosepiece should be upholstered 1 25
Slightly dazzling display 1 28
Examination with the reference medical device
Overall positive feedback on the RMD 4 1, 2, 6, 13
Whistle-like sound made by the RMD was not disturbing 4 1, 2, 10, 13
a Part of an uncomfortable nosepiece; patient rated the investigational device as ‘‘good.’’
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minutes in duration (SD¼ 0.83; 95% CI: 2.82–2.17) as
measured in all the examined patients.
Safety Objective
No safety concerns as defined by VA loss, AEs,
SAEs, or SADEs were observed.
Discussion
The U.S. Food and Drug Administration has
already approved perimetric devices for home mon-
itoring, and these devices have been successful in
previous clinical trial settings.23,24 The home-based
structural imaging of the retina is the next logical step.
We believe that the described, rapid spOCT exami-
nation could be an important development in the
longitudinal three-dimensional monitoring of retina
structure pathologies. In the present study, we showed
that the spOCT was capable of delivering OCT
images with an adequate resolution under real-life
conditions, thus enabling measurements of retinal
thickness in AMD patients with various associated
pathologies, such as cataract, dry eye, and tremor.
The intra- and interrater reliability coefficients of
.0.95 suggest both the high consistency and the
reproducibility of the measurements. The very short
acquisition time could have positive effects on
improving the patient’s comfort and reducing poten-
tial acquisition artifacts, which is especially important
in elderly individuals. Most importantly, patients with
a limited fixation could benefit from the short
acquisition time. Such brief measurements could
further improve clinical efficiency, which was previ-
ously slow, regarding new concepts for the use of
decentralized OCT imaging.25
The system was specifically designed for handling
by patients and not by health care professionals in
order to allow automatic image acquisition in
patients’ homes or in nursing homes. This need is
exacerbated by the mounting pressure to monitor a
growing number of patients with chronic eye diseas-
es26 in an increasingly resource-constrained environ-
ment.27 For example, in the United States, over 100
million people with chronic diseases account for
about 75% of health care expenditures.28 The possible
benefit of the presented OCT device arises from the
potential of telehealth and the delivery of more
efficient, convenient, cost-effective, and patient-cen-
tered care.29–31
The self-OCT monitoring of patients at home
would avoid referrals and save travel time and costs
as well as involve patients in their long-term care at a
high level. Compared with commercial desktop OCT
devices, the cost has been shown to be at least one
third that of similar devices because of optimized
design. Loans to purchasers (e.g., patients and health
care providers) could be made possible, depending on
the regulations in each country.
Validated components were also used for their
potential to reduce the size and weight of the device.
The rate of positive patient feedback on the
ophthalmology examination conducted using the
spOCT was comparable to that on the reference
desktop OCT device. Some other helpful comments
collected during the examination using spOCT will be
used to improve some of the device’s components,
particularly the nosepiece and the interface cavity.
The close examination of the distribution of the
retinal thickness data revealed some limitations
associated with the precision of the spOCT measure-
ments of the areas of interest. The differences in the
CRT measurements between the spOCT and the
reference device were not statistically significant, and
the mean difference of 4.52 lm was well within the
range of the mean differences found in pairwise
comparisons of six commercially available OCT
devices (2–77 lm).20 However, the Bland-Altman
plot (Fig. 3) shows that about one third of the spOCT
measurements deviated by more than 20 lm from the
reference value, and one outlier was as high as65.6
lm. This disparity may be attributed to the manual
quantification method required in the spOCT.
Moreover, the results of the quantitative OCT
analysis differed between various commercial ultra-
high-resolution OCT instruments because they
employed different postprocessing protocols and
relied on inconsistent definitions of retinal mar-
gins.32,33 Because of these technical disparities,
retinal thickness values are often not uniformly
measured by different OCT systems, especially
regarding abnormalities in the retinal tissue. Other
limitations of this study include the small number of
participants and the narrow inclusion criteria.
However, these limitations are acceptable in an
initial feasibility study.19
The results of this study showed that the new
device could also handle different sample resolutions
that were appropriate to clinical requirements. The
imaging information about the new device using a
high sample acquisition protocol was similar to that
of the reference OCT device. Because the fully
detailed OCT image looks natural to the human
eye, it may serve to promote visual discrimination in
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humans. However, these images are time-consuming
to acquire, and future studies should be conducted to
demonstrate the level of image redundancy that is
needed to achieve the maximum reliability of OCT
scans.34 Thus, further studies are warranted to
validate the system and to run fully automatic image
analyses using methods such as machine learning.
Automatic image analysis would be helpful in the
anti-vascular endothelial growth factor (anti-VEGF)
therapy. Anti-VEGF is currently the standard for the
treatment of neovascular AMD (nAMD), diabetic
macular edema, retinal vein occlusion, and other
vascular pathologies of the retina. Different treatment
protocols have been developed to optimize the benefit-
to-risk ratio and the cost-effectiveness of anti-VEGF
agents.35–38 Nevertheless, recently published data
under real-life conditions showed poor functional
results.39,40 In contrast, in a recent study the data
showed a positive association among more frequent
visits, repeated OCTs, and more injections, with a
better visual outcome.41 Furthermore, regarding the
detection of impending VA deterioration, evidence
showed that central foveal thickness measurement may
be a sensitive and early predictor of VA deteriora-
tion.42 Despite the sophisticated anti-VEGF protocols,
the follow-up decision to treat reflects only the best
possible estimation rather than an accurate decision
based on timely and true retinal measurements. Thus,
it may be speculated that, hypothetically, continuous
retinal monitoring with spOCT could close this
information gap and lead to a legitimated and
individualized treatment regimen. This approach could
not only open the best therapeutic window for the
optimal effect of a drug but also allow for the detection
of early conversion in fellow eyes.43,44 Additionally, the
optimization of the number of retreatments, the
reduction of in-clinic visits, and the improvement of
treatment logistics based on telehealth communication
systems would be provided.
In the future, it will be necessary to definenew criteria
for retreatment (interval) and to determine reliable
predictive factors, thusmeetingthereal-life requirements
of AMD and other diseases. In this context, OCT
telehealth45 may be a mechanism to facilitate the more
efficient and better delivery of medicine despite regula-
tory, economic, and technological obstacles.24,46–49 The
home-basedprimarycaremodelhas received increasing
attention worldwide.50–53 In many countries, the
population of patients who manage their own health
outside professional health care by employing home-
use medical devices is on the rise.54 Thus, the further
development of the spOCT device software, ergonom-
ics, and telecommunications will be the objective of
future research.
This study showed positive results for the
performance and safety of the newly developed,
robust, self-contained retina OCT scanner
MIMO_02 in an elderly population suffering from
AMD and could be applied beyond. In this setting,
our portable, relatively inexpensive, and patient-
operated OCT scanner showed promise as an
important aid to disease management and prompt
treatment decisions to safeguard patients’ health
and comfort. This important novel monitoring
device, combined with a machine learning software
that compiles the OCT data automatically and
enhanced with self-acting data communication,
may eventually transform the ways in which
patients with retinal diseases are followed and
treated into a telehealth loop that could be
described as ‘‘OCT singularity’’.
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